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ABSTRACT (word count: 240/250 words) 
Background & aims. All oral Direct-Acting Antivirals (DAA) have been shown to improve the 
liver function of patients with decompendsated cirrhosis but it is presently unknown whether this 
clinical improvement may lead to the delisting of some patients. The aim of this study was to assess 
if and which patients can be first inactivated due to clinically improvement and subsequently 
delisted in a real life setting.  
Methods 103 consecutive listed patients without hepatocellular carcinoma were treated with 
different DAA combinations in 11 European Centres between February 2014 and February 2015 
Results The cumulative incidence of inactivated and delisted patients by competing risk analysis 
was 15.5% and 0% at 24 weeks, 27.6% and 10.3% at 48 weeks, 33.3% and 19.2% at 60 weeks. The 
34 patients who were inactivated showed a median improvement of 3.4 points for MELD (Delta 
MELD,p<0.0001) and 2 points for Child-Pugh (Delta-Child-Pugh,p<0.0001). Three variables 
emerged from the most parsimonious Multivariate competing risk model as predictors of 
inactivation for clinical improvement, namely, baseline MELD classes (MELD16-20: HR=0.120; 
p=0.0005, MELD>20:HR=0.042; p<0.0001), Delta-MELD (HR=1.349; p<0.0001) and Delta-
Albumin (HR=0.307; p=0.0069) both assessed after12 weeks of DAAs therapy. 
Conclusions This study showed that all oral DAAs were able to reverse liver dysfunction and 
favoured the inactivation and delisting of about one patient out-of-three and one patient out-of-five 
in 60 weeks, respectively. Patients with lower MELD scores had higher chances to be delisted. The 
longer term benefits of therapy need to be ascertained. 
  
LAY SUMMARY 
The excellent efficacy and safety profile of the new drugs against Hepatitis C virus, the so called 
“Direct Acting Antivirals” or DAAs, have made antiviral therapy possible also for patients with 
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advanced liver disease and for those on the waiting list for liver transplantation (LT). This study 
shows for the first time that the DAAs may lead to a remarkable clinical improvement allowing the 
delisting of one patient out of 5.  
 
Introduction 
The availability of new Direct Acting Antivirals (DAAs) has radically changed the approach to the 
treatment of hepatitis C virus (HCV) infection and also the prognosis of patients with HCV-related 
liver disease. The excellent efficacy and safety profile of these drugs and the potential to use all 
interferon-free regimes, have made antiviral therapy possible also for patients with advanced liver 
disease and for those on the waiting list for liver transplantation (LT). 
Interim and preliminary data from on-going clinical trials indicate that new DAAs given to patients 
with decompensated cirrhosis are highly effective in eradicating HCV infection and may lead, in 
some cases, to a significant clinical improvement [1-6] with reversal of de-compensation. These 
data are prompting the liver transplant community to explore whether the same favourable results 
can be obtained in liver transplant candidates but, more importantly, whether they may eventually 
allow the inactivation/de-listing of some patients due to clinical improvement [7]. Several transplant 
centres across Europe have started using these drugs, but clinical trials or reports of field experience 
are lacking. 
To verify the validity of this new scenario, we initially conducted a survey focused on HCV 
positive liver transplant candidates with de-compensated cirrhosis without hepatocellular carcinoma 
(HCC) and who had been treated with the new DAAs at different European Liver Transplant 
Centres. The preliminary results of this survey were discussed at an “ad hoc” European Liver and 
Intestine Transplant Association (ELITA) monothematic conference in Milan and were the basis for 
the development of an extended database recording patients with HCV-related decompensated 
cirrhosis and no HCC, listed for transplantation and treated with second generation DAAs while on 
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the waiting list. The objective of this multicentre European study was to understand the impact of 
DAAs on inactivation/delisting due to clinical improvement in a real life setting.  
Patients and methods 
A Monothematic Conference organized by the ELITA regarding the use of second generation 
DAAs both before and after LT was held in Milan on 6 March 2015. This event allowed experts 
from several Liver Transplant Centres across Europe to share their experience on the day to day use 
of these novel treatments which became available about 1 year earlier. 
At the conference, it was decided to retrospectively collect data from patients listed for 
decompensated cirrhosis and consecutively treated with 2nd generation DAAs during the waiting 
period between February 2014 and February 2015 and were followed until 31 December 2015. 
Eleven European Centres participated to this study: Bergamo, Bologna, Milan Niguarda, Milan 
Policlinico, Montpellier, Paris Mondor, Villejuif Paris Paul Brousse, Palermo, Turin, Valencia and 
Vienna.  
Inclusion criteria 
Consecutive liver transplant candidates with decompensated HCV cirrhosis without HCC treated 
with second generation DAAs while listed for LT.  
Criteria for listing 
Basically, patients were listed if  they had a MELD score >15 or a MELD score < 15 with MELD 
exceptions such as refractory ascites not treatable with TIPS (8 cases), chronic hepatic 
encephalopathy (13 cases), hepato-pulmonary syndrome (2 cases) and refractory bleeding (2 cases). 
In addition, 11 patients were judged worth listing despite a MELD score <15 and no clear MELD 
exception. Overall 35 patients were listed with MELD <15. The distribution of patients with 
MELD< 15 was similar across centres.  
Exclusion criteria 
- HIV or HBV co-infected recipients. 
- DAA treatment started before listing 
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Definitions and patient stratifications  
In case of clinical improvement due to DAAs therapy the following definitions were used:  
Inactivation: patient is placed “on hold” due to clinical improvement based on clinical judgement of 
local investigator. For such a patient the clinician judges that, based on liver function and/or clinical 
improvements, LT is presently no longer indicated, but the patient is not removed from the list until 
a long term clinical improvement has been verified. Defining “clinical improvement leading to 
inactivation” was one the aims of the study. 
Delisting: patient is off the list because a durable clinical improvement has been verified based on 
clinical judgement of local investigator. 
End points 
The primary end points was the probability to be inactivated due to clinical improvement 
Secondary end-points included virological efficacy, DAA-related improvement of liver function, 
description of the objective criteria taken into account by investigators for considering inactivation 
and eventually delisting. 
Predictors of inactivation. 
Probability to be delisted due to durable clinical improvement 
To achieve these goals, the following parameters were retrospectively collected:  
Baseline: demographics, indication for LT, genotype, previous antiviral therapy, HCV-RNA levels, 
DAA regimen used (Sofosbuvir/Ribavirin-SOF/RBV or Sofosbuvir/Daclatasvir -SOF/DCV or 
Sofosbuvir/Ledipasvir -SOF/LDV or Sofosbuvir/Simeprevir- SOF/SMV) and duration, MELD 
score, C-P scores and individual components of MELD and C-P scores (bilirubin, INR, creatinine, 
albumin, ascites and encephalopathy). Cofactors for liver decompensation, such as alcohol 
consumption, bacterial infections, haemorrhagic events and portal vein thrombosis were also 
registered. 
During therapy and follow up: HCV-RNA levels at 4, 8, 12, 16 and 24 weeks. MELD, C-P scores 
and individual components of MELD and C-P scores (bilirubin, INR, creatinine, albumin, ascites 
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and encephalopathy) at 12 and 24 weeks. For those receiving ribavirin, median ribavirin dose was 
registered. 
Outcome. Seven clinical outcomes were identified and registered: 1) liver transplantation, 2) patient 
still waiting for a liver transplant, 3) death while waiting for transplant, 4) patient inactive in the 
transplant list due to clinical improvement, 5) patient delisted due to clinical improvement, 6) 
patient dropout due to other causes (e.g. clinical worsening, refused liver transplant) and 7) death 
after inactivation or delisting. 
Type and duration of antiviral treatment 
Planned duration of treatment was up to 48 weeks or until transplant for patients receiving 
SOF/RBV and up to 24 weeks or until transplant for those receiving SOF/DCV or SOF/LDV or 
SOF/SMV with or without RBV. DAAs combinations were used depending on genotype and drug 
availability.  
Ethical approval was not sought as the study utilised data provided in the course of normal patient 
care and no patient-identifiable data were collected.  
Statistical Analysis 
Descriptive statistical analysis was performed where data are expressed as median (interquartile 
range (IQR) or range). Categorical variables were compared with the Chi-square test or 2-sided 
Fisher’s exact test, continues variables were analysed by the Student t test or by Wilcoxon’s rank-
sum test as appropriate. McNemar's test or Bowker's test were used to compare categorical 
variables before and after treatment while paired student t test or Mann-Whitney U test was used for 
continues variables as appropriate.  
The Impact of DAA on liver functions (MELD, C-P score, bilirubin, creatinine, etc.) was assessed 
over time at 12 and 24 weeks after start of therapy. The same parameters were analysed comparing 
inactivated vs non inactivated patients. For patients with LT or death before the 24 weeks, we 
considered the last available value. The MELD and C-P score changes were also assessed 
stratifying patients in different MELD (<16, 16-20 and >20) and C-P classes (B and C) at baseline.  
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Cumulative incidence curves for inactivation from waiting list were constructed considering time to 
inactivation and time to LT and time to death as competing risks [8]. Further, cumulative incidence 
curves for delisting were constructed considering time to delisting and time to LT and time to death 
as competing risks. Time to inactivation, time to delisting, time to LT and time to death were 
measured from the date of treatment start. 
Clinical and demographic characteristics at baseline were tested as prognostic factors for 
inactivation. The prognostic significance of clinical and demographic characteristics was 
determined by univariable Cox Regression Model for Competing Risks [9]. Further, changes of 
MELD, C-P scores and their individual components after 12 weeks of treatment were tested as 
possible dynamic predictors for inactivation using the same method. Changes of MELD and C-P 
sores were tested as continuous and as two level-categorical data. The level of MELD and C-P 
improvement (Delta MELD and Delta C-P at 12 weeks) were identified using an outcome-oriented 
approach, as proposed by Contal and O’Quigley[10]. Variables that were lower than p<0.1 on 
univariable analysis were tested into multivariable Cox regression models for Competing Risks, and 
the most parsimonious model was selected. Based on the selected multivariate model, the 
inactivation cumulative incidence was estimated for hypothetical patients to show the effect of the 
variables included. The inactivation cumulative incidence of simulated patients was estimated by 
the function  
,  = 
 − 	−Λ
,  ,  = 
 − −Λ
,  where 
Λ
, Λ
, is the empirical cumulative distribution hazard of inactivation and  are the 
individual covariates [9]. All analyses were performed using SAS software (version 9.4; SAS 
Institute Inc., Cary, NC). 
Results 
Between February 2014 and February 2015, 134 patients were listed for decompensated cirrhosis 
without HCC; of these, 103 were treated with DAA and 31 were not. Reasons for not treating were 
the following: 21 patients were considered too close to LT (13 had a MELD score >25 and 8 a 
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MELD score between 18 and 24); 6 patients were included in a study protocol of pre-emptive post 
LT DAA therapy; 2 patients declined the opportunity to be treated before LT and for 2 patients the 
compassionate drug did not arrive in time. 
Baseline features of the 103 treated patients are reported in Table 1. The median (IQR) follow up 
was 51.9 (32.9-67.4) weeks. Median MELD and C-P scores at baseline were 16 and 10, 
respectively. Of note, 50.5% of the patients had been treated with SOF and RBV, 34% with SOF 
+DCV, 8.7% with SOF + LDV and 6.8% with SOF+ SMV. The treatment duration for each type of 
DAA treatment is reported in suppl. Table 1. 
Virological outcomes 
Virological clearance, defined as HCV-RNA < LLOQ with a detection threshold of 15 IU, was 
observed in 66 patients after 4 weeks of therapy (rapid virological response-RVR, 66/103, 64%) 
and in 32 additional patients after 12 weeks (early virological response-EVR, 98/100=98%), Fig.1. 
Three patients could not be evaluated for EVR as two had received a LT and one had died before 
week 12. Of the 2 patients who remained viremic after 12 weeks, 1 underwent LT and the second 
had viral re-activation after he temporarily stopped SOF/RBV for 10 days due to acute pancreatitis. 
Considering the 52 patients receiving SOF/RBV (which was planned for up to 48 weeks or until 
LT), 28 completed the entire course of therapy and 4 had a relapse. These 4 patients are presently 
on re-treatment with a dual DAAs regimen. Twenty-two patients underwent LT while on therapy 
and the remaining 2 patients died of sepsis while on therapy. These 2 patients had a baseline MELD 
score of 17 and 22. Only one of the 22 patients who had received a LT, had a viral relapse after the 
operation and is under dual DAA therapy. 
Fifty-one patients were treated with SOF/DCV (n=35) or SOF/LDV (n=9) or SOF/SMV (n=7). 
They all completed their course of treatment and none relapsed while listed. One patient treated 
with SOF/DCV had a relapse after LT and he is presently under retreatment with IFN/SOF/DCV 
and RBV. 
Clinical Outcome 
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Of the entire cohort of 103 patients, 4 (3.9%) died while on active list (2 of sepsis, 1 of massive 
bleeding and 1 of heart failure after TIPS placement), 41 (39.8%) underwent LT, 22 (21.3%) are 
waiting for a transplant and 34 (33%) were inactivated from the transplant list due to clinical 
improvement. Of these 34, 21 were delisted and one died from massive bowel infarction 4 months 
after the end of DAA treatment. The 2 remaining patients were delisted for reasons not related to 
clinical improvement  (one for cardiac problems and the other declined the transplant).  
Impact of DAA on liver function  
The impact of DAA on liver function was assessed on 102 of the 103 patients because one patient 
died of sepsis before 12 weeks of treatment. 
a-Impact on MELD score. 
The evolution of MELD score from start of DAA therapy to 24 weeks afterwards is shown in suppl. 
Table 2. Overall, the median MELD score improved from 15.5 to 14.0 (p=0.0008). 
b-Impact on C-P score:  
Median C-P score improved from 10.0 before DAA to 8.0 on week 24 after start of treatment 
(p<0.001) (suppl. Table 2). 
c- Impact of DAA on individual variables reflecting liver function 
Details of the impact of DAA on bilirubin, prothrombin time, creatinine, albumin, ascites and 
encephalopathy are shown in suppl. Table 3, 4 and 5. The more relevant biochemical changes after 
24 weeks from start of therapy were a median increase of albumin by 0.3 g/dL (p<0.0001) and a 
median reduction of bilirubin by 0.4 mg/dL (p=0.004).  In addition, the percentage of patients with 
refractory ascites halved from 26% at baseline to 13% after 24 weeks (p<0.0001) and stage 2 HE 
regressed in almost 2 thirds of affected patients (p<0.0001) (suppl. Table 4 and 5). 
The improvement of MELD score, C-P score and individual variables was already detectable at 12 
weeks as shown in suppl. Table 6. 
Impact of DAA on inactivation and delisting. 
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a- Overall, 34 patients were considered to improve clinically enough to be inactivated on the 
waiting list. Of these, 21 patients (62%) were de-listed after a more prolonged period of clinical 
improvement. During follow-up the cumulative incidence of inactivated patients at 24, 48 and 60 
weeks after the start of DAAs therapy, as assessed by competing risk analysis was 15.5%, 27.6% 
and 33.3% (Fig. 2A) while, the cumulative incidence of delisted patients at the same time points 
was  0%,10.3% and 19,2% respectively (Fig. 2B).  
The median (IQR) time from the start of treatment to the inactivation and delisting was 25.6 (16.9-
38.0) and 52.4 (37.1-59.3) week respectively. The minimum time interval between start of therapy 
and inactivation or delisting was 12 and 27 weeks respectively.  
b- Clinical features of inactivated and delisted patients 
The clinical features of patients who could be inactivated for clinical improvement, were compared 
with those observed in patients who were non-inactivated (Table2). Patients who were inactivated 
had a baseline median MELD and C-P score of 14 and 9, respectively. The median improvement 
after 24 weeks from start of therapy was minus 3.4 points for MELD (Delta MELD, p<0.0001) and 
minus 2 points for C-P (Delta C-P, p<0.0001). The greatest improvement of the MELD score was 
observed within the first 12 weeks from start of therapy, from 14 to 12 during the first 12 weeks and 
from 12 to 10.5 from week 12 to week 24 (Fig.3A). In contrast Child-Pugh steadily improved until 
week 24 (Fig.3B). 
The more relevant biochemical changes after 24 weeks from start of therapy in patients who could 
be inactivated for clinical improvement, were a median increase of albumin by 0.5 g/dL (p=0.0002), 
a median reduction of bilirubin by 0.9 mg/dL (p=0.0036) and median reduction in INR by 0.13 
points (p=0.002) (Table 2). In contrast, creatinine, which was in the normal range in most cases at 
starting of DAA, did not change significantly over the study period. In addition in inactivated 
patients ascites improved dramatically (all cases of refractory ascites at baseline became treatable 
with diuretics after 24 weeks) and stage 2 HE regressed in all patients but 1 (suppl. Tables7 and 8). 
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The improvement of MELD score, C-P score and individual variables in inactivated patients was 
already detectable at 12 weeks as shown in suppl Table 9. 
The twenty-one patients that were delisted, had the following MELD score at start of therapy: 24 
(1 patients), 20 (1 patient), 17 (1 patient), 16 (1 patient), 15 (3 patients), 14 (4 patients), 13 (3 
patients), 12 (3 patients), 11 (3 patients) and 9 (1 patient). Sixteen of them (77%) showed a 
complete regression of signs of liver decompensation. These patients no longer had ascites or any 
kind of fluid retention at delisting and were off any diuretic therapy. When chronic HE was present, 
it also completely regressed and patients were off any medical therapy. These patients reported they 
felt well and became very active. Their median MELD score at delisting was 10 (8-12). The 
remaining 5 patients (23%) still presented some fluid retention at delisting requiring low doses of 
diuretics. Two of these 5 patients had a refractory ascites at start of therapy. The MELD score at 
delisting of these 5 patients was 6, 8, 9 and 13 (2 patients). (Fig.4) 
c- Predictors of inactivation for clinical improvement. 
We considered both static factors (demographics and clinical characteristics at baseline) and various 
dynamic parameters (improvement of C-P, MELD and of their individual components after 12 
weeks of DAAs therapy) in the univariable Cox proportional analysis for Competing Risks (suppl. 
Table 10). Three static factors, namely, baseline MELD score, baseline Child-Pugh score and 
baseline INR were significantly associated with inactivation. Among the dynamic parameters, 5 
emerged as significant predictors (p<0.05) of inactivation, namely, 12-week Delta MELD and 12-
week Delta C-P (as continuous and two-level categorical variables), Delta albumin, Delta bilirubin 
and Delta INR. 
All variables with a p<0.05 at univariable analysis were then tested in a multivariable Cox 
regression models for Competing Risks analysis and the most parsimonious model with the 
following three variables was selected: baseline MELD categories (MELD 16-20: HR=0.120, 
p=0.0005; MELD >20: HR=0.042. p<0.0001), continuous 12-week Delta MELD (HR=1.349; 
p<0.0001) and continuous 12-week Delta Albumin (HR=0.307; p=0.0069) (Table 3). These results 
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indicate that MELD and albumin improvement after 12 weeks of treatment are associated with a 
higher probability of the patient being inactivated; while a higher MELD score at baseline decreases 
this probability. Therefore, for the same improvement of MELD and albumin, a patient starting with 
a MELD score lower than 16 has a higher probability of being inactivated compared to a patient 
starting from a higher MELD score.  
To show the combined effects of these variables, we estimated the cumulative incidence of 
inactivation of 6 hypothetical patients as reported in Figure 5.  
d- Baseline MELD class stratification, Delta MELD and  inactivation for clinical improvement. 
Patients were stratified at baseline into 3 different MELD classes (<16, 16-20 and >20) and the 
resulting rates of inactivation were reported taking into account the MELD changes after 12 weeks 
of therapy (FIG 5). Among patients with MELD score <16, the probability of inactivation was 27.3, 
85.7 and 100% in patients with 12-week delta MELD<2, 2 to 4 and > 4, respectively. In contrast, in 
patients with a baseline MELD score ranging from 16 to 20, the probability of inactivation was 10.5 
% in patients with 12-week delta MELD <2, but 16.7 and 42.9% in patients with 12-week delta 
MELD of 2-4 or 4. Eventually, among patients with baseline MELD score > 20, inactivation was 
observed only in 2 patients with a 12-week delta MELD > 4 (Fig 6). These 2 patients had a rapid 
deterioration of liver function 4 and 6 weeks before the start of DAA therapy (ACLF associated 
with sepsis) 
Relisting of inactivated/delisted patients 
One inactivated patient had to be relisted for the occurrence of a small HCC. No patient so far had 
to be relisted for liver  decompensation. 
 
Discussion 
All oral direct-acting antiviral (DAAs) have revolutionized the management of patients with 
chronic HCV infection and SVR rates higher than 90% can be obtained in patients with 
compensated cirrhosis [1-6]. However in patients with decompensated cirrhosis efficacy data of 
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DAA are still scarce and it is presently unknown whether viral clearance may result in a lasting 
improvement of signs of liver decompensation.  Since preliminary data from phase 3 studies [1,2] 
show that a meaningful biochemical and clinical improvement can be obtained in some patients 
with HCV-related de-compensated cirrhosis on DAA therapy it is  possible that some patients listed 
for LT due to decompensated cirrhosis can improve their liver function to an extent that some of 
them can be inactivated from the waiting list and eventually delisted. This would be similar to what 
was observed in the past [11] when HBV-liver transplant candidates with decompensated cirrhosis 
were treated with nucleos/tide (NUC). Almost one third of these HBV patients were eventually 
delisted while on NUC therapy and their clinical improvement could be maintained for up to 5 
years. Whether DAA-related clinical improvement may lead to the delisting of some HCV patients 
is therefore a major and still unanswered question that may have important consequences both at the 
patient level and also in terms of organ-sparing. Indeed, we are currently facing a “cohort effect” 
with many listed patients who could not be treated in the past and that are now eligible to be treated 
with the new DAAs. In Europe the percentage of patients listed for LT due HCV liver diseases, 
ranges from 25% to 60% and half of them have decompensated cirrhosis [12]. Therefore pre LT 
DAA treatment and associated delisting could significantly reduce the need for LT and save organs. 
The aims of the present study were to investigate the magnitude of liver function improvement due 
to DAA, to determine the percentage of patients who can be inactivated/delisted after DAA 
treatment and to find possible predictors for inactivation/delisting. 
Several important results emerge from this multicentre retrospective European study: 
- all oral DAA therapies are highly effective in patients with decompensated cirrhosis listed for LT 
as more than 90% of treated patients maintained a lasting viral suppression before transplantation, 
irrespective of the DAA regimen. 
- despite the very high virological response obtained in a population which was previously 
considered as "difficult to treat", improvement of liver function leading to inactivation on the 
waiting list and eventual delisting, is frequent but not constant. Taking into account the competing 
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risks of LT, dropout due to other causes and death before LT, the 24, 48 and 60 week-probabilities 
of inactivation from the waiting list were 15.5, 27.6 and 33.3% while the probabilities of delisting 
were 0%, 10.3% and 19.2% at the same time points. Inactivated patients showed a significantly 
more pronounced improvement than patients who were not inactivated with a median decrease of 
MELD score of 3.4 points, which was achieved during the first 12 weeks of therapy. In contrast, the 
MELD score of patients who were not inactivated remained grossly unchanged (table 2). The effect 
of DAA treatment on C-P score in inactivated patients was equally relevant with a decrease of 2 
points from baseline to week 24, but occurred later than the MELD improvement. This indicates 
that although DAA effect on biochemical parameters of liver function is rapid, the effect on the two 
pivotal symptoms of decompensated cirrhosis, namely ascites and encephalopathy, is slower and 
merits a further period of observation to make the clinician confident enough to propose delisting. 
Delisting usually followed inactivation by at least 3 months since the usual tendency of the treating 
clinician was to inactivate patients who improved significantly but not to remove them from the list 
until a long-term clinical improvement was verified.  
- It is worth noting that around one fourth of the patients in this multi centre cohort had a MELD 
score at listing lower than 15, which is below the generally accepted threshold of benefit. However, 
among the 35 patients with MELD < 15, 24 had been listed for MELD exceptions and 11 (8.2% of 
the entire cohort) without a clear MELD exception. It is highly likely that clinicians felt more 
confident offering DAA therapy to patients with lower MELD scores because these patients would 
not be too close to LT and would better tolerate the drugs. This is confirmed by the finding that the 
vast majority of untreated patients during the study period had a much higher MELD score.   
Based on multivariate competing risks analysis and simulations, we propose the following strategy 
taking into account MELD at listing and evolution of MELD and albumin over the first 12 weeks of 
DAA treatment: 
- Patients with a MELD score < 16. These patients have a low probability of dying on the waiting 
list (overall mortality of 2% in this series) or alternatively they may be served by MELD exceptions 
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for their access to transplant. These patients also have a very high probability of achieving an SVR 
(>80%) and an overall chance to improve clinically and being inactivated in 50% of the cases (Fig 
5). Therefore, DAA treatment can be recommended with the aim of achieving either viral 
elimination and delisting because of liver function improvement, or transplantation with no risk of 
HCV recurrence. We propose to inactivate these patients over the first 12 weeks of treatment in 
order to ensure at least a one month of full viral suppression to prevent HCV recurrence (6) and to 
evaluate delta MELD and delta Albumin on week 12. In case of a relevant MELD and albumin 
improvement (delta MELD > 2 and delta albumin> 0.5g/dL), these patients may subsequently be 
inactivated for another 12 week-period due to a high probability of improvement of ascites and 
encephalopathy on week 24 (Fig 3) and eventual delisting. Patients who do not improve under 
DAAs on week 12, should be re-activated and considered for LT under the MELD exception rule if 
acceptable. 
- Patients with a MELD score between 16 and 20. The chances of being inactivated are around 20% 
and therefore the decision to treat pre or post LT should be considered only on the individual basis 
considering the expected waiting time and clinical conditions (slowly progressive versus rapidly 
progressive disease ie acute on chronic liver failure, ACLF) as well as the competing risk of LT. In 
stable patients, the same initial policy as in patients with baseline MELD < 16 can be advised, with 
subsequent MELD and albumin reassessment on week 12. In patients with MELD improvement > 4 
and albumin increase > 0.5, a further 12-week period of inactivation should be considered because 
of a reasonable chance of further improvement of ascites and encephalopathy (Fig 5). Hopefully the 
early assessment of biochemical changes at 12 weeks should prevent futile transplantation in 
patients likely to be delisted. 
- Patients with a MELD score >20. The only 2 patients that were delisted had developed an ACLF 
induced by sepsis early before starting DAAs. In addition, for these candidates, there is a significant 
competing risk of early LT or death both before and after LT. The awareness of these competing 
risks and cost-effectiveness considerations suggest that DAA treatment should be considered after 
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LT rather than before LT. This final consideration refers to the possibility of a MELD purgatory 
effect, which may hamper the access to LT in patients with minimal to mild MELD decrease 
without a clinically relevant improvement, here again pleading in favor of DAA treatment post 
transplant. 
There are some limitations to the current study. Firstly, the retrospective design and the lack of 
clear criteria for delisting at the conception of the study; indeed, the identification of de-listing 
criteria was a secondary end-point of the study. Secondly, some centres did not have the entire 
spectrum of DAA available. Therefore the impact of DAA on delisting might even be higher when 
optimal DAA therapies are used. Thirdly, the follow up is too short to assess the long-term risk of 
death, of further deterioration and of development of HCC. 
In conclusion, the present study shows that in decompensated cirrhotics, second generation DAAs 
are very effective and often lead to a remarkable clinical improvement allowing inactivation and 
eventually delisting in a substantial number of patients. In addition to the individual benefit to the 
patients, the strategy of inactivating patients with significant MELD and albumin improvement on 
week 12 may result in saving around 30% of organs dedicated to transplantation of HCV patients, 
with an important effect on organ shortage, particularly in programs with a high prevalence of HCV 
liver diseases. A word of caution is to be mentioned regarding how long the clinical improvement 
will last. We suggest designing long-term multinational observational studies on patients who have 
been listed for decompensated HCV cirrhosis and subsequently delisted because of clinical 
improvement. It will be critical to assess the long-term risks of death, further re-deterioration and 
development of HCC more specifically. These factors still need to be verified.  
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Table 1.Baseline characteristics of treated patients (N=103) 
Variables Values  
Age Median (Range) 54 (37-71) 
Male N (%) 70 (68.0) 
HCV-RNA IU/mL Median (Range) 237,000 (1,334-100,000,000) 
Genotype, N (%) 
1a 20 (19.4) 
1b 40 (38.8) 
2 3 (2.9) 
3 20 (19.4) 
4 20 (19.4) 
MELD Median (Range) 16 (6-31) 
MELD classes, N (%) 
<16 51 (49.5) 
16-20 38 (36.9) 
>20 14 (13.6) 
Child-Pugh Median (Range) 10 (7-13) 
Child-Pugh classes, N (%) A 5-6 0 
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B 7-9 46 (44.6) 
C 10-14 57 (55.3) 
Ascites, N (%) 
None 15 (14.6) 
Medically controlled 61 (59.2) 
Medically uncontrolled 27 (26.2) 
Encephalopathy, N (%) 
None 54 (52.4) 
Medically controlled 48 (46.6) 
Medically uncontrolled 1 (1.0) 
DAAs treatment, N (%) 
SOF/RBV 52 (50.5) 
SOF/LDV ± RBV 9 (8.7) 
SOF/DCV ± RBV 35 (34.0) 
SOF/SMV ± RBV 7 (6.8) 
MELD, Mayo-model for End stage Liver Disease; DAAs, Direct Acting Antivirals; SOF, Sofosbuvur; RBV, 
Ribavirin; LDV, Ledipasvir; DCV, Daclatasvir; SMV, Simeprevir 
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Table  2. Change of biochemical parameters, MELD and Child Pugh after 24 weeks of follow up 
comparing Non inactivated vs Inactivated patients (N=102)# 
 
Non inactivated  
(68 patients) 
Inactivated 
 (34 patients) 
 
Variables N Median (IQR) N Median (IQR) P-value* 
Albumin at start of therapy 64 2.9 (2.7-3.25) 31 3.1 (2.8-3.6) 0.141 
Albumin at 24 weeks 59 3.1 (2.8-3.5) 33 3.5 (3.3-4.3) <.0001 
Delta Albumin (24weeks-start) 58^ 0.14 (-0.1-0.4) 31^^ 0.5 (0.2-0.9) 0.0002 
Bilirubin at start of therapy 68 3.35 (2.36-5.1) 34 2.455 (1.63-3.05) 0.0046 
Bilirubin at 24 weeks 64 2.8 (1.95-4.515) 34 1.38 (0.99-2) <.0001 
Delta Bilirubin (24weeks-start) 64§ -0.045 (-1.035-0.555) 34 -0.925 (-1.62--0.13) 0.0036 
INR at start of therapy 68 1.52 (1.305-1.765) 34 1.385 (1.27-1.53) 0.0145 
INR at 24 weeks 63 1.49 (1.39-1.68) 34 1.25 (1.2-1.39) <.0001 
Delta INR (24weeks-start) 63† 0.02 (-0.13-0.11) 34 -0.13 (-0.26-0.01) 0.002 
Creatinine at start of therapy 68 0.9 (0.745-1) 34 0.905 (0.71-1.11) 0.9462 
Creatinine at 24 weeks 63 0.9 (0.7-1.03) 34 0.875 (0.71-1) 0.8707 
Delta Creatinine (24w-start) 63† 0.02 (-0.09-0.11) 34 0.0075 (-0.09-0.11) 0.7053 
MELD at start of therapy 68 16 (14-19) 34 14 (12-16) 0.0019 
MELD at 24 weeks 68 15.65 (13-19) 34 10.5 (9-13) <.0001 
Delta MELD (24weeks-start) 68 0 (-2-2) 34 -3.4 (-5--1) <.0001 
CPT at start of therapy 68 10 (9-11) 34 9 (8-10) 0.0009 
CPT at 24 weeks 66 9 (8-11) 34 6.5 (6-7) <.0001 
Delta CPT (24weeks-start) 66‡ 0 (-1-1) 34 -2 (-4--1) <.0001 
# 1 patient who died before week 12 is not considered in the analysis. 
*Mann-Whitney U test; ^4 data not used because patients supplemented with albumin, 2 data missing 
because of LT before week 12 and 4 missing data at week 24; ^^2 data not used because patients 
supplemented with albumin; §2  data missing at week 24 because of LT before  week 12; †2 data missing at 
week 24 because of LT before 12 weeks and 3 missing data at week 24; ‡2 missing data at week 24 because 
of LT before week 12.  
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Table 3. Competing risk analyses of inactivation from list: multivariable model. 
Variable Category HR (IC95%) p-value 
Delta MELD at 12 weeks c.v. 1.349 (1.2-1.516) <.0001 
MELD at baseline <16 1 ref 
 
16-20 0.12 (0.036-0.396) 0.0005 
  >20 0.042 (0.013-0.138) <.0001 
Delta Albumin at 12 weeks c.v. 0.307 (0.13-0.724) 0.0069 
c.v. = continuous variable 
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FIGURE LEGENDS 
 
Figure 1. Virological outcome of 103  liver listed patients with de-compensated 
cirrhosis and treated with DAAs based therapy while listed. 
DAAs, Direct Acting Antivirals; RVR, Rapid Virological Response; EVR, Early Virological 
response; SOF, Sofosbuvir; RBV, Ribavirin. * 3 patients could not be evaluated for EVR (see text). 
 
Figure 2. Competing risk Cumulative incidence of patients that were inactivated, dropped 
out, underwent LT or died (panel A) and of those that were delisted, dropped out, underwent 
LT or died (panel B).  
 
Figure 3. MELD and Child-Pugh score changes over time in inactivated (N=34) and non 
inactivated patients (N=68).  
MELD score changes at 12 and 24 weeks from start of therapy are shown in panel A.  Child-Pugh 
score changes at 12 and 24 weeks from start of therapy are shown in panel B.  I, Inactivated (blue); 
NI = Non Inactivated (red). 1 patient who died before week 12 is not considered in the analysis. 
 
Figure 4. Delisted patients: individual  MELD score at baseline and at delisting. 
 
Figure 5. Estimated cumulative incidence of inactivation based on the 3 variables that 
emerged from the multivariable model, namely baseline MELD, 12w Delta MELD and 
12w Delta albumin. Six hypothetical patients are presented. 
 
Figure 6. Inactivated patients stratified by MELD at baseline and Delta MELD after 12 
weeks (N=102). 1 patient who died before week 12 is not considered in the analysis. 
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Figure 5
  
N° of patients 51 N° of patients 38 N° of patients 13
MELD at strat of 
therapy MELD < 16 MELD 16-20 MELD > 20
49.14 70.36 88.86 45.71 42.64 62.14 23.36 30.43 47.64
(32.86-60.57) (58.86-87.14) (68.36-96.79) (34.00-58.57) (33.64-64.43) (52.29-67.71) (17.14-37.21) (30.43-30.43) (26.36-67.64)
3/7 (42.9%) 0/8 (0.0%) 0/1 (0.0%) 2/4 (50.0%)
Weeks of follow-up            
Median (IQR)
!MELD " 4 !MELD < 2 !MELD 2-4 !MELD " 4
N° of inactivated 
patients(%) 9/33 (27.3%) 12/14 (85.7%) 4/4 (100%) 2/19 (10.5%) 2/12 (16.7%)
N° of inactivated 
patients(%) 25/51 (49.0%) 7/38 (18.4%) 2/13 (15.38%)
!MELD after 12 weeks !MELD < 2 !MELD 2-4 !MELD " 4 !MELD < 2 !MELD 2-4
Figure 6
  
DAA therapy in patients with decompensated cirrhosis listed for liver 
transplantation: competing risk of  delisting  due to  clinical improvement. 
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